UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 187

Sortiert nach

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Volltextzugriff (PDF)

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers

International journal of oncology, 2022-03, Vol.60 (3), p.1, Article 35

2022

Volltextzugriff (PDF)

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Volltextzugriff (PDF)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Volltextzugriff (PDF)

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [ 177 Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

Korean Journal of Radiology, 2024, 25(2), , pp.179-188

2024

Volltextzugriff (PDF)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.883-892

2019

Volltextzugriff (PDF)

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, obesity & metabolism, 2015-07, Vol.17 (7), p.630-638

2015

Volltextzugriff (PDF)

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Current opinion in urology, 2020-01, Vol.30 (1), p.98

2020

Volltextzugriff (PDF)

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.891-899

Davis, T. M. E.

2014

Volltextzugriff (PDF)

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Volltextzugriff (PDF)

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.523-532

2011

Volltextzugriff (PDF)

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1513-1520

2017

Volltextzugriff (PDF)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.567-576

2011

Volltextzugriff (PDF)

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.487-494

2015

Volltextzugriff (PDF)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Archives of Endocrinology and Metabolism, 2018-08, Vol.62 (4), p.424-430

2018

Volltextzugriff (PDF)

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1253-1262

2016

Volltextzugriff (PDF)

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Volltextzugriff (PDF)

Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury

Molecular medicine reports, 2020-07, Vol.22 (1), p.33-42

2020

Volltextzugriff (PDF)

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

Oncotarget, 2016-10, Vol.7 (43), p.69625-69637

2016

Volltextzugriff (PDF)

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Oncotarget, 2017-01, Vol.8 (2), p.3581-3590

2017

Volltextzugriff (PDF)

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation

World journal of gastroenterology : WJG, 2015-06, Vol.21 (24), p.7436-7442

2015

Volltextzugriff (PDF)

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Volltextzugriff (PDF)

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.850-858

2011

Volltextzugriff (PDF)

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Volltextzugriff (PDF)

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Revista española de cardiología (English ed.), 2017-12, Vol.70 (12), p.1143-1144

2017

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Aktive Filter

KollektionIEEE Xplore Digital Library

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(65)

Publikationsform

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Dipeptides - Therapeutic Use
(152)
Humans
(144)
Male
(93)
Science & Technology
(78)
Life Sciences & Biomedicine
(76)
Female
(66)
Middle Aged
(62)
Animals
(58)
Adult
(51)
Aged
(39)
Dipeptides - Pharmacology
(38)
Adamantane - Analogs & Derivatives
(36)
Diabetes Mellitus, Type 2 - Drug Therapy
(35)
Treatment Outcome
(32)
Adamantane - Therapeutic Use
(31)
Dipeptides - Administration & Dosage
(26)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(26)
Dipeptides - Adverse Effects
(25)
Rats
(24)
Endocrinology & Metabolism
(23)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [ 177 Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation

Baseline differences in the SAVOR trial

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Aktive Filter

Suchergebnisse filtern